Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Affiliations

¹ University of Arizona Cancer Center, Tucson, AZ, USA. Alison.Stopeck@stonybrookmedicine.edu.
² Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
³ Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
⁴ Cancer Research UK Experimental Cancer Medicine Centres, St James's University Hospital, Leeds, UK.
⁵ Weston Park Hospital, University of Sheffield, Sheffield, UK.
⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
⁷ Center for Comprehensive Gynecology Clinic, Mannheim, Germany.
⁸ National Cancer Center Hospital, Tokyo, Japan.
⁹ Instituto de Investigación Sanitaria General Gregorio Marañón, Universidad Complutense, Madrid, Spain.
¹⁰ Tom Baker Cancer Centre, Calgary, AB, Canada.
¹¹ Cross Cancer Institute, Edmonton, AB, Canada.
¹² Carolina Urologic Research Center, Myrtle Beach, SC, USA.
¹³ Lancaster Urology, Lancaster, PA, USA.
¹⁴ Urology Associates, Christchurch, New Zealand.
¹⁵ The Urology Center of Colorado, Denver, CO, USA.
¹⁶ Sarah Cannon Research Institute, Nashville, TN, USA.
¹⁷ Amgen Inc., Thousand Oaks, CA, USA.

Published Erratum

Alison T Stopeck et al. Support Care Cancer. 2016 Jan.

. 2016 Jan;24(1):457-458.

doi: 10.1007/s00520-015-2985-1.

¹ University of Arizona Cancer Center, Tucson, AZ, USA. Alison.Stopeck@stonybrookmedicine.edu.
² Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
³ Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
⁴ Cancer Research UK Experimental Cancer Medicine Centres, St James's University Hospital, Leeds, UK.
⁵ Weston Park Hospital, University of Sheffield, Sheffield, UK.
⁶ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
⁷ Center for Comprehensive Gynecology Clinic, Mannheim, Germany.
⁸ National Cancer Center Hospital, Tokyo, Japan.
⁹ Instituto de Investigación Sanitaria General Gregorio Marañón, Universidad Complutense, Madrid, Spain.
¹⁰ Tom Baker Cancer Centre, Calgary, AB, Canada.
¹¹ Cross Cancer Institute, Edmonton, AB, Canada.
¹² Carolina Urologic Research Center, Myrtle Beach, SC, USA.
¹³ Lancaster Urology, Lancaster, PA, USA.
¹⁴ Urology Associates, Christchurch, New Zealand.
¹⁵ The Urology Center of Colorado, Denver, CO, USA.
¹⁶ Sarah Cannon Research Institute, Nashville, TN, USA.
¹⁷ Amgen Inc., Thousand Oaks, CA, USA.

No abstract available

Erratum for

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Stopeck AT, et al. Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Support Care Cancer. 2016. PMID: 26335402 Free PMC article. Clinical Trial.